A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic pre ...

Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share By . Reuters. Published May 16, 2025, 11:43 a.m. ET.

Ozempic pens being assembled at the Novo Nordisk factory in Hillerod, Denmark. (Charlotte de la Fuente for The Wall Street Journal) Shares of Europe's most valuable company rallied around 3.6% in ...

Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs In a statement Monday, Novo Nordisk defended its pricing structure.

Also Read: Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds NVO stock has lost close to 50% of its value in the last year and is down over 23% year-to-date.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...